Navigation Links
ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
Date:10/25/2007

ADVENTRX Presents Results at 2007 AACR-NCI-EORTC International Conference

SAN DIEGO, Oct. 25 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today it presented preclinical results demonstrating that ANX-514, the company's docetaxel emulsion product candidate, reduced hypersensitivity reactions without impacting pharmacokinetics or antitumor activity when compared to Taxotere(R) (docetaxel). The results were presented at the American Association of Cancer Research (AACR), National Cancer Institute (NCI) and European Organization and Treatment of Cancer (EORTC) International Conference "Molecular Targets and Cancer Therapeutics" in San Francisco on October 25, 2007 by Mark J. Cantwell, Ph.D., vice president, research and development. Docetaxel is an anti-cancer agent that is approved to treat breast, non-small cell lung, prostate, gastric and head and neck cancers, and is marketed under the brand name Taxotere(R). Annual sales of Taxotere in 2006 were approximately $2.2 billion.

"We feel the reduced hypersensitivity reactions associated with ANX-514 would be a benefit to patients and a way to differentiate ANX-514," stated Evan M. Levine, chief executive officer of ADVENTRX. "We remain focused on initiating a marketing-enabling clinical trial of ANX-514 later this year, pending appropriate regulatory clearances."

In an established animal model, anaphylactoid clinical reactions were observed following Taxotere administration, including decreased respiration, swelling and tremors. Furthermore, decreases in blood pr
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection of Mammalian Cells
2. Sensient reduces debt, must pay settlement
3. Optimizing pfuturbo DNA Polymerase Amplification Reactions with Perfect Match PCR Enhancer
4. Measuring Gene Silencing Effects by RT-PCR Without RNA Isolation
5. Detection of Morphine and Morphine-Glucuronide in Saliva or Urine with a Rapid and Simple Method Without Derivatization on the Varian 500-MS
6. DHC 2007: Without fuller IT adoption, health costs might drain Americas wealth
7. Wisconsin wont get Georgia biotech without a fight
8. Some Madisonians content without city wireless
9. Researchers report development of embryonic stem cells without destroying embryo
10. Succeeding online without a Web site
11. Encrypted data without the fuss

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... The agenda for Arrowhead’s 2010 Personaliz...to take place on February 22-24, 2010 in Philadelp...nce we will highlight key issues in forming partne... experiences. , Minneapol...Arrowhead’s 2010 Personalized Medicine Part...
(Date:11/5/2009)... Nov. 5 The endangered black-foote... U.S. This rare carnivore feeds on prairie dogs. ...and often entire population die-offs in towns occu... implemented a ferret breeding program and has bee...rmerly native habitat. Unfortunately, plague can ...
(Date:11/5/2009)...lif., Nov. 5 ThermoGenes...nnovative products for processing and storing adul... quarter of fiscal 2010. ,, For the quarter end...es of $5.2 million, a 15 percent increase over rev...ago. The Company said the key contributors to the ...
(Date:11/5/2009)...v. 5 BioSpecifics Techno... company developing first-in-class collagenase-bas... for the third quarter ended September 30, 2009. ...of this year, the FDA,s Arthritis Advisory Committ... approval of XIAFLEX(TM) for the treatment of Dupu...
Breaking Biology Technology:Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5
... Biotech Products, L. P. Supports Program to Recog...o recognize the,extraordinary commitment of oncolo...ounced its support of CURE magazine,s 2008 Extraor...nors one of the thousands of,exceptional oncology ...cation, compassion and helpfulness. Last year, mor...
...ands the Company,s Clinical Stage Product Portfoli...uticals,Inc. today announced that it is has comple...and commercialize products under AstraZeneca,s IP ...tors (AI) in combination with,estrogen and progest...Meditrina,s clinical stage product portfolio which...
...ERSBURG, Md., Feb. 6 Iomai Corporation,(Nasdaq: ...ompany,s,president and chief executive officer, wi...onference in New York City on Tuesday, Feb. 12. Mr... Time in the in New Amsterdam,Suite of the Waldorf...ate and clinical milestones and,detail the results...
Other Biology Technology:Call for Entries - 2008 CURE Extraordinary Healer Award for Oncology Nursing 2Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca 2Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca 3Iomai CEO to Speak at BIO CEO & Investor Forum on Feb. 12 2
(Date:11/9/2009)...-- Genencor, a division of Danisco, has won the na...n Institute of Chemical Engineers (AIChE) for its ... ethanol. Yesterday, Robert Davis, Chair of the AI...n Steele, who is Marketing Director, Biomass Enzym...n Kelley, who is Senior Engineer, Biomass Applicat...
(Date:11/8/2009)...rdue University have discovered a new approach for...uries using nano-spheres that could be injected in...nthetic "copolymer micelles" are drug-delivery sph...00 times smaller than the diameter of a red blood ...liver drugs for cancer treatment and other therapi...
(Date:11/6/2009)...y with their arboreal hosts. But new research sugg...s of choice, the ants can get destructive to neigh...ovember issue of the American Naturalist , is the... and it reopens a centuries-old debate on the rela...tain species of plants and trees have cozy relatio...
Breaking Biology News(10 mins):Genencor Wins The American Institute of Chemical Engineers (AIChE) Sustainable Energy Award For Accellerase(R) Cellulosic Ethanol Enzymes 2Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3Ants are friendly to some trees, but not others 2Biomimetic engineering design can replace spaghetti tangle of nanotubes in novel material 12400 1Biomimetic engineering design can replace spaghetti tangle of nanotubes in novel material 12400 2Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions 4509 1Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions 4509 2Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions 4509 3Streamwood Hospital Opens New Childrens Center to Meet Vital Community Need 47557 1Streamwood Hospital Opens New Childrens Center to Meet Vital Community Need 47557 2
...The legacy of nuclear weapons and nuclear energy d...ozens of sites across the United States and many m...e uranium is transported through ground water as u...um immobilization in contaminated ground water and...ic molecules known as electron donors to stimulate...
...in the UK and funded by the UK Biotechnology and B... a new drug discovery tool to identify a new playe...nding could spark a completely new class of drugs ...is week in Nature Chemical Biology researchers a...askatchewan graduate Dr Grant Churchill, explain h...
...ed an algorithm that meshes existing data to produ...respond to stimuli. Using this new method, Whitehe...logy scientists have analyzed alpha-synuclein toxi...t cell survival. Misfolded copies of the alpha-syn...rkinson,s disease. , RELEVANCE: Until now, data o...
Other Biology News:Patience pays off with methanol for uranium bioremediation 2Canadian scientist mines drugs database for new diabetes treatment 2Calculating gene and protein connections in a Parkinson's disease model 2Calculating gene and protein connections in a Parkinson's disease model 3Calculating gene and protein connections in a Parkinson's disease model 4
Mouse Anti-20S Proteasome alpha1, 2, 3, 5, 6, & 7-Subunits Monoclonal Antibody, Unconjugated, Clone MCP231 from Calbiochem
...een the 500 l and 4 ml centrifugal concentrators. ...spin products with low internal surface and membra...olutions. ,Available with a choice of PES, Cell...highest flexibility for process optimisation. ,A...
Mouse Anti-HSV-2 Glycoprotein G-2 Monoclonal Antibody, Unconjugated, Clone H1206 from Meridian Life Science, Inc.
...Region By immunoblotting the antibody reacts again...free MMP-2 or MMP-2 bound to TIMP-2. affinity isol... Solution in 0.01 M phosphate buffered saline, pH ...e. synthetic peptide corresponding to the hinge re...
Biology Products: